Literature DB >> 25898962

MET Mutation Associated with Responsiveness to Crizotinib.

Saiama N Waqar1, Daniel Morgensztern2, Jennifer Sehn3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25898962      PMCID： PMC4408879          DOI： 10.1097/JTO.0000000000000478

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Authors:  Monica Kong-Beltran; Somasekar Seshagiri; Jiping Zha; Wenjing Zhu; Kaumudi Bhawe; Nerissa Mendoza; Thomas Holcomb; Kanan Pujara; Jeremy Stinson; Ling Fu; Christophe Severin; Linda Rangell; Ralph Schwall; Lukas Amler; Dineli Wickramasinghe; Robert Yauch
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Diagnostic utility of targeted next-generation sequencing in problematic cases.

Authors:  Jennifer K Sehn; Ian S Hagemann; John D Pfeifer; Catherine E Cottrell; Christina M Lockwood
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

3.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

4.  Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.

Authors:  Yoshinari Asaoka; Motohisa Tada; Tsuneo Ikenoue; Motoko Seto; Mitsuho Imai; Koji Miyabayashi; Keisuke Yamamoto; Shinzo Yamamoto; Yotaro Kudo; Dai Mohri; Yoshihiro Isomura; Hideaki Ijichi; Keisuke Tateishi; Fumihiko Kanai; Seishi Ogawa; Masao Omata; Kazuhiko Koike
Journal:  Biochem Biophys Res Commun       Date:  2010-03-21       Impact factor: 3.575

5.  Ethnic differences and functional analysis of MET mutations in lung cancer.

Authors:  Soundararajan Krishnaswamy; Rajani Kanteti; Jonathan S Duke-Cohan; Sivakumar Loganathan; Wanqing Liu; Patrick C Ma; Martin Sattler; Patrick A Singleton; Nithya Ramnath; Federico Innocenti; Dan L Nicolae; Zheng Ouyang; Jie Liang; John Minna; Mark F Kozloff; Mark K Ferguson; Viswanathan Natarajan; Yi-Ching Wang; Joe G N Garcia; Everett E Vokes; Ravi Salgia
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531
  5 in total
  22 in total

1.  MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:  Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal:  Transl Lung Cancer Res       Date:  2015-12

2.  Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.

Authors:  Guanggui Ding; Jian Wang; Peikun Ding; Yuxin Wen; Lin Yang
Journal:  Cancer Biol Ther       Date:  2019-02-11       Impact factor: 4.742

Review 3.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

4.  Has MET met its match?

Authors:  Alain Borczuk; Daniel Paucar; Balazs Halmos
Journal:  Ann Transl Med       Date:  2016-03

5.  Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Authors:  Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist
Journal:  Lung Cancer       Date:  2019-05-11       Impact factor: 5.705

6.  Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.

Authors:  Edward B Garon; Paige Brodrick
Journal:  Drugs       Date:  2021-02-27       Impact factor: 9.546

Review 7.  Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.

Authors:  Joshua K Sabari; Fernando Santini; Isabella Bergagnini; W Victoria Lai; Kathryn C Arbour; Alexander Drilon
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

Review 8.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

9.  MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Authors:  Rebecca S Heist; Hyo Sup Shim; Shalini Gingipally; Mari Mino-Kenudson; Long Le; Justin F Gainor; Zongli Zheng; Martin Aryee; Junfeng Xia; Peilin Jia; Hailing Jin; Zhongming Zhao; William Pao; Jeffrey A Engelman; A John Iafrate
Journal:  Oncologist       Date:  2016-03-28

10.  A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Authors:  Saiama N Waqar; Mary W Redman; Susanne M Arnold; Fred R Hirsch; Philip C Mack; Lawrence H Schwartz; David R Gandara; Thomas E Stinchcombe; Natasha B Leighl; Suresh S Ramalingam; Saloni H Tanna; Ryan S Raddin; Katherine Minichiello; Jeffrey D Bradley; Karen Kelly; Roy S Herbst; Vassiliki A Papadimitrakopoulou
Journal:  Clin Lung Cancer       Date:  2020-10-14       Impact factor: 4.785
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.